• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

耐利奈唑胺和突变表型的金黄色葡萄球菌分离株在成人囊性纤维化患者中的快速出现。

Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient.

机构信息

Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.

出版信息

Antimicrob Agents Chemother. 2013 Oct;57(10):5186-8. doi: 10.1128/AAC.01392-13. Epub 2013 Aug 5.

DOI:10.1128/AAC.01392-13
PMID:23917314
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3811410/
Abstract

Linezolid has emerged as an important therapeutic option for the treatment of Staphylococcus aureus in patients with cystic fibrosis. We report the rapid emergence, upon treatment with linezolid, of linezolid-resistant S. aureus clinical isolates through the accumulation of resistance-associated 23S rRNA mutations, together with acquisition of an altered mutator phenotype.

摘要

利奈唑胺已成为治疗囊性纤维化患者金黄色葡萄球菌感染的重要治疗选择。我们报道了在利奈唑胺治疗过程中，由于耐药相关 23S rRNA 突变的积累，以及获得改变的突变体表型，导致利奈唑胺耐药的金黄色葡萄球菌临床分离株的迅速出现。

相似文献

1
Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient.耐利奈唑胺和突变表型的金黄色葡萄球菌分离株在成人囊性纤维化患者中的快速出现。
Antimicrob Agents Chemother. 2013 Oct;57(10):5186-8. doi: 10.1128/AAC.01392-13. Epub 2013 Aug 5.
2
Detection of linezolid-resistant Staphylococcus aureus with 23S rRNA and novel L4 riboprotein mutations in a cystic fibrosis patient in Spain.在西班牙一名囊性纤维化患者中检测到具有23S rRNA和新型L4核糖体蛋白突变的耐利奈唑胺金黄色葡萄球菌。
Antimicrob Agents Chemother. 2013 May;57(5):2428-9. doi: 10.1128/AAC.00208-13. Epub 2013 Mar 4.
3
Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis.一名囊性纤维化患者肺部感染治疗期间耐利奈唑胺金黄色葡萄球菌的出现。
Int J Antimicrob Agents. 2006 Apr;27(4):300-2. doi: 10.1016/j.ijantimicag.2005.11.008. Epub 2006 Mar 9.
4
Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.金黄色葡萄球菌对利奈唑胺的耐药性：耐药表型的特征与稳定性
J Infect Dis. 2002 Dec 1;186(11):1603-7. doi: 10.1086/345368. Epub 2002 Nov 4.
5
Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.利奈唑胺在不同剂量下的体外药代动力学-药效学模型中对具有和不具有高突变表型的金黄色葡萄球菌和粪肠球菌菌株的活性。
Antimicrob Agents Chemother. 2010 Apr;54(4):1443-52. doi: 10.1128/AAC.01022-09. Epub 2010 Jan 25.
6
Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus.金黄色葡萄球菌中rRNA操纵子突变拷贝的持续存在及利奈唑胺耐药性的快速重新出现。
J Antimicrob Chemother. 2007 Sep;60(3):649-51. doi: 10.1093/jac/dkm246. Epub 2007 Jul 10.
7
Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients.耐(linezolid)ST36 型甲氧西林耐药金黄色葡萄球菌与两名儿科囊性纤维化患者长时间(linezolid)治疗相关。
J Antimicrob Chemother. 2010 Mar;65(3):442-5. doi: 10.1093/jac/dkp494. Epub 2010 Jan 20.
8
Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.俄亥俄州克利夫兰市囊性纤维化患者长期治疗后出现耐利奈唑胺金黄色葡萄球菌。
Antimicrob Agents Chemother. 2011 Apr;55(4):1684-92. doi: 10.1128/AAC.01308-10. Epub 2011 Jan 24.
9
Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis.运用焦磷酸测序法鉴定耐利奈唑胺金黄色葡萄球菌和表皮葡萄球菌23S rRNA基因V结构域中的点突变。
Eur J Clin Microbiol Infect Dis. 2007 Mar;26(3):161-5. doi: 10.1007/s10096-007-0261-0.
10
Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.金黄色葡萄球菌对利奈唑胺的耐药性：基因剂量效应、稳定性、适应性代价及交叉耐药性
Antimicrob Agents Chemother. 2008 Apr;52(4):1570-2. doi: 10.1128/AAC.01098-07. Epub 2008 Jan 22.

引用本文的文献

1
Antibacterial activity of Chinese propolis and its synergy with β-lactams against methicillin-resistant Staphylococcus aureus.蜂胶的抗菌活性及其与β-内酰胺类抗生素对耐甲氧西林金黄色葡萄球菌的协同作用。
Braz J Microbiol. 2022 Dec;53(4):1789-1797. doi: 10.1007/s42770-022-00807-0. Epub 2022 Jul 28.
2
Australian propolis ethanol extract exerts antibacterial activity against methicillin-resistant Staphylococcus aureus by mechanisms of disrupting cell structure, reversing resistance, and resisting biofilm.澳大利亚蜂胶乙醇提取物通过破坏细胞结构、逆转耐药性和抵抗生物膜等机制对耐甲氧西林金黄色葡萄球菌发挥抗菌活性。
Braz J Microbiol. 2021 Dec;52(4):1651-1664. doi: 10.1007/s42770-021-00547-7. Epub 2021 Jul 7.
3
In-Host Emergence of Linezolid Resistance in a Complex Pattern of Toxic Shock Syndrome Toxin-1-Positive Methicillin-Resistant Colonization in Siblings with Cystic Fibrosis.在囊性纤维化的兄弟姐妹中，存在一株表现出复杂表型耐甲氧西林的 金黄色葡萄球菌定植，并同时伴有中毒性休克综合征毒素-1 阳性，该菌在宿主内出现了利奈唑胺耐药。
Toxins (Basel). 2021 Apr 28;13(5):317. doi: 10.3390/toxins13050317.
4
Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.泰利万星在急性肺部恶化期成年囊性纤维化患者中的药代动力学。
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01914-19.
5
Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Resistant to Linezolid in a Cystic Fibrosis Patient.耐甲氧西林金黄色葡萄球菌在囊性纤维化患者中对利奈唑胺的出现和体内遗传进化。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00720-18. Print 2018 Dec.
6
Emergence of cfr-Mediated Linezolid Resistance in a Methicillin-Resistant Staphylococcus aureus Epidemic Clone Isolated from Patients with Cystic Fibrosis.在从囊性纤维化患者中分离出的耐甲氧西林金黄色葡萄球菌流行克隆中出现cfr介导的利奈唑胺耐药性。
Antimicrob Agents Chemother. 2015 Dec 14;60(3):1878-82. doi: 10.1128/AAC.02067-15.
7
Tedizolid Phosphate: a Next-Generation Oxazolidinone.磷酸泰地唑胺：新一代恶唑烷酮类药物。
Infect Dis Ther. 2015 Feb 24;4(1):1-14. doi: 10.1007/s40121-015-0060-3.

本文引用的文献

1
The emerging problem of linezolid-resistant Staphylococcus.耐(linezolid)利奈唑胺(Staphylococcus)葡萄球菌的新兴问题。
J Antimicrob Chemother. 2013 Jan;68(1):4-11. doi: 10.1093/jac/dks354. Epub 2012 Sep 4.
2
Resistance to linezolid in a methicillin-susceptible Staphylococcus aureus clinical isolate without previous exposure to oxazolidinones.耐万古霉素金黄色葡萄球菌临床分离株对利奈唑胺的耐药性，该分离株之前未接触过恶唑烷酮类药物。
Int J Med Microbiol. 2012 Jul;302(3):145-7. doi: 10.1016/j.ijmm.2012.03.001. Epub 2012 May 9.
3
Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.成人囊性纤维化患者静脉注射和口服利奈唑胺的药代动力学。
Antimicrob Agents Chemother. 2011 Jul;55(7):3393-8. doi: 10.1128/AAC.01797-10. Epub 2011 Apr 25.
4
Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.俄亥俄州克利夫兰市囊性纤维化患者长期治疗后出现耐利奈唑胺金黄色葡萄球菌。
Antimicrob Agents Chemother. 2011 Apr;55(4):1684-92. doi: 10.1128/AAC.01308-10. Epub 2011 Jan 24.
5
Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance.囊性纤维化中的细菌超突变，不仅与抗生素耐药性有关。
Clin Microbiol Infect. 2010 Jul;16(7):798-808. doi: 10.1111/j.1469-0691.2010.03250.x.
6
Pharmacological issues of linezolid: an updated critical review.利奈唑胺的药理学问题：更新的批判性评价。
Clin Pharmacokinet. 2010 Jul;49(7):439-47. doi: 10.2165/11319960-000000000-00000.
7
Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.利奈唑胺在不同剂量下的体外药代动力学-药效学模型中对具有和不具有高突变表型的金黄色葡萄球菌和粪肠球菌菌株的活性。
Antimicrob Agents Chemother. 2010 Apr;54(4):1443-52. doi: 10.1128/AAC.01022-09. Epub 2010 Jan 25.
8
Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients.耐(linezolid)ST36 型甲氧西林耐药金黄色葡萄球菌与两名儿科囊性纤维化患者长时间(linezolid)治疗相关。
J Antimicrob Chemother. 2010 Mar;65(3):442-5. doi: 10.1093/jac/dkp494. Epub 2010 Jan 20.
9
Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).通过使用恶唑烷酮类药物利奈唑胺和替唑肟（TR-700）进行选择，鉴定出金黄色葡萄球菌菌株中的新型核糖体突变。
Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74. doi: 10.1128/AAC.00871-09. Epub 2009 Sep 14.
10
Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.金黄色葡萄球菌对利奈唑胺的耐药性：基因剂量效应、稳定性、适应性代价及交叉耐药性
Antimicrob Agents Chemother. 2008 Apr;52(4):1570-2. doi: 10.1128/AAC.01098-07. Epub 2008 Jan 22.